Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhejiang Taimei Medical Technology Co Debt-to-Equity?
Zhejiang Taimei Medical Technology CoFRA:A2V +0.40%11 Debt-to-Equity is 0.05 as of Dec. 2025, which is 25% above its 10-year median of 0.04. GuruFocus rates FRA:A2V with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 565 Healthcare Providers & Services companies, Zhejiang Taimei Medical Technology Co ranks better than 85.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
FRA:A2V'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.06
Current: 0.05
During the past 5 years, the highest Debt-to-Equity Ratio of Zhejiang Taimei Medical Technology Co was 0.06. The lowest was 0.02. And the median was 0.04.
FRA:A2V's Debt-to-Equity is ranked better than 85.66% of 565
companies
in the Healthcare Providers & Services industry
Industry Median: 0.43
vs FRA:A2V: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zhejiang Taimei Medical Technology Co Debt-to-Equity Related Terms
Zhejiang Taimei Medical Technology Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Taimei Medical Technology Co Debt-to-Equity Chart
Zhejiang Taimei Medical Technology Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Debt-to-Equity
0.06
0.04
0.02
0.03
0.05
Zhejiang Taimei Medical Technology Co Semi-Annual Data
FRA:A2V vs VEEV, BTSG, TEM: Debt-to-Equity Comparison
For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Taimei Medical Technology Co Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zhejiang Taimei Medical Technology Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a Debt-to-Equity of 0.05 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. This is 25% above median its historical median of 0.04. Over the past decade, Zhejiang Taimei Medical Technology Co's Debt-to-Equity has ranged from 0.02 to 0.06. According to the industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #81 out of 565 companies in the Healthcare Providers & Services industry, placing it in the top 14.3%.
Is Zhejiang Taimei Medical Technology Co's Debt-to-Equity too high?
Zhejiang Taimei Medical Technology Co's current Debt-to-Equity of 0.05 is 25% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.06. The Healthcare Providers & Services industry median Debt-to-Equity is 0.43. Zhejiang Taimei Medical Technology Co's value of 0.05 is 88.4% below this industry median. Based on the distribution chart, Zhejiang Taimei Medical Technology Co ranks #81 out of 565 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #81 out of 565 companies for Debt-to-Equity. This places Zhejiang Taimei Medical Technology Co in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.43. Zhejiang Taimei Medical Technology Co's value of 0.05 is 88.4% below this benchmark. Historically, Zhejiang Taimei Medical Technology Co's own Debt-to-Equity has ranged from 0.02 to 0.06 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.43, Zhejiang Taimei Medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Taimei Medical Technology Co's current Debt-to-Equity of 0.05 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Taimei Medical Technology Co's current Debt-to-Equity is 0.05, which is 25% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current Debt-to-Equity of 0.05. The current Debt-to-Equity is 0.05, which is 25% above median its 10-year median of 0.04 and 88.4% below the Healthcare Providers & Services industry median of 0.43. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current Debt-to-Equity is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score
Get the complete analysis for FRA:A2V
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2V has been successfully added to your 
